Synergistic growth-inhibitory effects of two tyrosine kinase inhibitors, dasatinib and PKC412, on neoplastic mast cells expressing the D816V-mutated oncogenic variant of KIT.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples